| Literature DB >> 29081356 |
Melissa García-Caballero1, Ana R Quesada1, Miguel A Medina2, Manuel Marí-Beffa3.
Abstract
Zebrafish, an amenable small teleost fish with a complex mammal-like circulatory system, is being increasingly used for drug screening and toxicity studies. It combines the biological complexity of in vivo models with a higher-throughput screening capability compared with other available animal models. Externally growing, transparent embryos, displaying well-defined blood and lymphatic vessels, allow the inexpensive, rapid, and automatable evaluation of drug candidates that are able to inhibit neovascularisation. Here, we briefly review zebrafish as a model for the screening of anti(lymph)angiogenic drugs, with emphasis on the advantages and limitations of the different zebrafish-based in vivo assays.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29081356 DOI: 10.1016/j.drudis.2017.10.018
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851